Skip to content

Menu

LexBlog, Inc. logo
CommunitySub-MenuPublishersChannelsProductsSub-MenuBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAboutContactResourcesSubscribeSupport
Join
Search
Close

Genentech Files Suit Alleging Eli Lilly’s Taltz® Product Infringes a Newly Issued Genentech Patent

By Seth E. Cockrum on July 16, 2018
Email this postTweet this postLike this postShare this post on LinkedIn
The Great Seal of the US Gold

On July 2, 2018, Genentech filed suit against Eli Lilly and Company (“Lilly”) in the Southern District of California alleging Lilly’s Taltz® infringes newly issued U.S. Patent 10,011,654 (“the ʼ654 patent”).  According to the complaint, the ʼ654 patent issued at 12:00 am Eastern time on July 3, 2018, and the complaint was filed immediately thereafter.

Taltz® was first approved in the United States in 2016 and is currently approved for the treatment of adults with active psoriatic arthritis or moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.   Lilly also recently announced that Taltz® met the primary and key secondary endpoints in a Phase 3 study evaluating the safety and efficacy of Taltz® for the treatment of Ankylosing Spondylitis.

The active ingredient in Taltz® is ixekizumab, a humanized monoclonal antibody specific for interleukin 17A.  Ixekizumab functions by blocking the activity of interleukin 17A, a pro-inflammatory cytokine.   The newly issued ʼ654 patent is titled “Antibodies Directed to IL-17A/IL-17F Heterodimers.”  Claim 1 recites “[a]n isolated humanized monoclonal antibody that binds to an IL-17A/IL-17F heterodimer comprising the polypeptide of SEQ ID NO: 3 and the polypeptide of SEQ ID NO: 4 with or without their associated signal peptides.”  Genentech alleges that ixekizumab binds to the heterodimer specified in the claim, and thus infringes that claim.

In its prayer for relief, Genentech requests that instead of being granted a permanent injunction, it be awarded “a running or ongoing royalty adequate to compensate Genentech for ongoing infringement.” Genentech further alleges that prior to filing the lawsuit, it notified Lilly that the ʼ654 patent would soon issue and offered Lilly a license at a royalty rate to be determined by arbitration, but Lilly declined.  Taltz® reportedly generated U.S. revenue of $486 million in 2017.

We will continue to keep you apprised of further developments.

Photo of Seth E. Cockrum Seth E. Cockrum
Email
  • Posted in:
    Health Care
  • Blog:
    Biosimilars Law Bulletin
  • Organization:
    Rothwell Figg
  • Article: View Original Source

LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center

New to the Network

  • Boston ERISA & Insurance Litigation Blog
  • Stridon News and Insights
  • Taft Class Action & Consumer Insights
  • Labor and Employment Law Insights
  • Age of Disruption
Copyright © 2022, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo